Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

2024-515687-31-01 Protocol ADO-01-24 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 9 Jul 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol ADO-01-24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 84
Countries 1
Sites 4

Patients suffering from cancer without further treatment options.

Key facts

Sponsor
Adamed Pharma S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Jul 2025 → ongoing
Decision date (initial)
2025-01-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients suffering from cancer without further treatment options.

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Adamed Pharma S.A.

Sponsor organisation
Adamed Pharma S.A.
Address
Ul. Mariana Adamkiewicza 6a, Pienkow Pienkow
City
Czosnow
Postcode
05-152
Country
Poland

Scientific contact point

Organisation
Adamed Pharma S.A.
Contact name
Blanka Seklecka

Public contact point

Organisation
Adamed Pharma S.A.
Contact name
Blanka Seklecka

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ongoing, recruiting 84 4
Rest of world 0

Investigational sites

Poland

4 sites · Ongoing, recruiting
Uniwersyteckie Centrum Kliniczne
Klinika Onkologii i Radioterapii, Gdański Uniwersytet Medyczny, Ul. Debinki 7, 80-211, Gdansk
Umed Clinical Trials Sp. z o.o.
Klinika Onkologii Klinicznej, Bud A-2, Ul. Pomorska 251, Lodz
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków / Oddział Badań Wczesnych Faz, Ul. Wilhelma Konrada Roentgena 5, 02-781, Warsaw
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Oddział Onkologii Klinicznej, Ul. Mikolaja Kopernika 50, 31-501, Cracow

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2025-07-09 2025-08-05

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-08 Poland Acceptable with conditions
2025-01-21
2025-01-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-28 Poland Acceptable
2025-05-19
2025-05-25
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-11 Poland Acceptable
2025-10-30
2025-11-03
4 NON SUBSTANTIAL MODIFICATION NSM-2 2026-06-02 Poland Acceptable
2025-10-30
2026-06-02